Latest News about NVS
Recent news which mentions NVS
Novo Nordisk Moves Amycretin Into Phase 3 Trials For Weight Management, Becomes Europe's Largest Company
June 13, 2025
From Benzinga
Novartis' Fabhalta Delivers Hemoglobin Gains, Reduces Fatigue In Patients With Rare Blood Disorder
June 12, 2025
From Benzinga
2 Dividend Growth Stocks to Buy and Hold Forever
June 06, 2025
From Motley Fool
From Benzinga
From TalkMarkets
The Smartest Vanguard ETF to Buy With $500 Right Now
May 21, 2025
From Motley Fool
From Benzinga
From Benzinga
Protagonist/Johnson & Johnson Partnered Drug Shows Significant Skin Clearance In Pivotal Psoriasis Study
May 09, 2025
From Benzinga
From Benzinga
BioNTech Appoints Novartis Executive As Finance Chief, Reaffirms 2025 Outlook Focusing on Oncology Expansion
May 05, 2025
From Benzinga
Humana Does Not Alter 2025 Outlook Despite Sales Miss And Medicare Membership Decline
April 30, 2025
From Benzinga
Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million
April 30, 2025
From Benzinga
Novartis Q1 Earnings Beat Street View, CEO 'Confident' In Delivering Upgraded Guidance
April 29, 2025
From Benzinga
US Stock Futures Edge Higher Tuesday: Expert Warns Of 'Perfect Volatility Storm' With Major Earnings And Economic Data Due This Week
April 29, 2025
From Benzinga
From Benzinga
Earnings Scheduled For April 29, 2025
April 29, 2025
From Benzinga
These 2 Top Dividend Stocks Are Making Moves to Avoid the Impact of Tariffs: Are They Buys?
April 26, 2025
From Motley Fool
From Benzinga
S&P 500, Nasdaq Futures Rise After Stocks Dip Amid Trump's Jabs At Powell, Strong Yen Gives Nikkei A Volatile Start
April 21, 2025
From Benzinga
2 Dividend Stocks Defying the Tariff-Fueled Market Correction to Buy and Hold Forever
April 17, 2025
From Motley Fool
Novartis Commits $23 Billion To Expand US Manufacturing Over Five Years, Despite Tariffs Uncertainties
April 11, 2025
From Benzinga
Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline
April 09, 2025
From Benzinga
Cell Therapy Maker Legend Biotech Is An 'Attractive Opportunity' Due To No Material Tariff Exposure: Analyst
April 08, 2025
From Benzinga
3 Health Care Stocks Whale Activity In Today's Session
April 08, 2025
From Benzinga
From Benzinga
FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals
April 01, 2025
From Benzinga
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.